12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glybera alipogene tiparvovec regulatory update

Amsterdam Molecular said it received a request from EMA's CHMP for additional information on Glybera to treat lipoprotein lipase (LPL) deficiency by March 8. The committee indicated a final decision on Glybera could be made by May. Last month, the European Commission asked for more information from the...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >